These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 4156797

  • 21. How do antipsychotic drugs work?
    Iversen LL.
    Neurosci Res Program Bull; 1975 Aug; 13 Suppl():29-51. PubMed ID: 241033
    [No Abstract] [Full Text] [Related]

  • 22. Dopaminergic blocking effects of antipsychotic drugs.
    Bunney BS.
    J Psychiatr Res; 1974 Aug; 11():72-3. PubMed ID: 4156793
    [No Abstract] [Full Text] [Related]

  • 23. Histochemical studies on the distribution of catecholamines and 5-hydroxytryptamine after intraventricular injections.
    Fuxe K, Ungerstedt U.
    Histochemie; 1968 Aug; 13(1):16-28. PubMed ID: 5741831
    [No Abstract] [Full Text] [Related]

  • 24. Brain catecholamine content and turnover in aging rats.
    Carfagna N, Trunzo F, Moretti A.
    Exp Gerontol; 1985 Aug; 20(5):265-9. PubMed ID: 4092759
    [Abstract] [Full Text] [Related]

  • 25. Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug -mezilamine- with weak cataleptogenic properties.
    Uzan A, Le Fur G, Mitrani N, Kabouche M, Donadieu AM.
    Life Sci; 1978 Jul 17; 23(3):261-73. PubMed ID: 29181
    [No Abstract] [Full Text] [Related]

  • 26. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.
    Creese I, Burt DR, Snyder SH.
    Science; 1976 Apr 30; 192(4238):481-3. PubMed ID: 3854
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of the turnover of the brain dopamine after treatment with the gammaaminobutyrate: 2-oxyglutarate transaminase inhibitor aminooxyacetic acid.
    Andén NE.
    Naunyn Schmiedebergs Arch Pharmacol; 1974 Apr 30; 283(4):419-24. PubMed ID: 4278500
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O.
    Neuroscience; 1978 Apr 30; 3(9):773-83. PubMed ID: 30919
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Amantadine and catecholamine uptake.
    Herblin WF.
    Biochem Pharmacol; 1972 Jul 15; 21(14):1993-5. PubMed ID: 4649347
    [No Abstract] [Full Text] [Related]

  • 37. Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
    Kety SS.
    Semin Psychiatry; 1972 Aug 15; 4(3):233-8. PubMed ID: 4155537
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Influence of sexual differentiation on striatal and limbic catecholamines.
    Leret ML, González MI, Tranque P, Fraile A.
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1987 Aug 15; 86(2):299-303. PubMed ID: 2882921
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.